"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
MeSH Number(s)
B04.820.650.589.650.350.400
B04.909.777.731.589.650.350.400
Concept/Terms
HIV-1- HIV-1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
- HIV-I
- Human immunodeficiency virus 1
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in Harvard Catalyst Profiles by year, and whether "HIV-1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 82 | 9 | 91 |
1995 | 78 | 6 | 84 |
1996 | 103 | 4 | 107 |
1997 | 110 | 10 | 120 |
1998 | 129 | 9 | 138 |
1999 | 130 | 9 | 139 |
2000 | 128 | 22 | 150 |
2001 | 101 | 32 | 133 |
2002 | 108 | 19 | 127 |
2003 | 108 | 22 | 130 |
2004 | 112 | 20 | 132 |
2005 | 126 | 17 | 143 |
2006 | 129 | 31 | 160 |
2007 | 127 | 22 | 149 |
2008 | 121 | 36 | 157 |
2009 | 136 | 33 | 169 |
2010 | 159 | 33 | 192 |
2011 | 133 | 41 | 174 |
2012 | 168 | 37 | 205 |
2013 | 163 | 32 | 195 |
2014 | 145 | 34 | 179 |
2015 | 130 | 28 | 158 |
2016 | 117 | 26 | 143 |
2017 | 94 | 43 | 137 |
2018 | 112 | 30 | 142 |
2019 | 88 | 43 | 131 |
2020 | 106 | 43 | 149 |
2021 | 100 | 25 | 125 |
2022 | 100 | 7 | 107 |
2023 | 69 | 1 | 70 |
2024 | 14 | 1 | 15 |
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lancet HIV. 2024 Apr; 11(4):e222-e232.
-
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS Comput Biol. 2024 Mar; 20(3):e1011518.
-
Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART. PLoS One. 2024; 19(3):e0299942.
-
Early Initiation of Antiretroviral Therapy Preserves the Metabolic Function of CD4+ T Cells in Subtype C Human Immunodeficiency Virus 1 Infection. J Infect Dis. 2024 Mar 14; 229(3):753-762.
-
Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLoS One. 2024; 19(3):e0298542.
-
"Block and lock" viral integration sites in persons with drug-free control of HIV-1 infection. Curr Opin HIV AIDS. 2024 May 01; 19(3):110-115.
-
A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol. 2024 Mar 19; 98(3):e0172023.
-
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-a2a. Cell. 2024 Feb 29; 187(5):1238-1254.e14.
-
HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies. Viruses. 2024 Feb 13; 16(2).
-
Proliferation of HIV-1 reservoir cells: The delusion of infinite growth. J Exp Med. 2024 Mar 04; 221(3).